Shares of
CureVac were up about 40% Monday after its CEO Franz-Werner Haas
said in an interview with the German financial news site Boerse Online over the weekend that he was hopeful its vaccine will be approved by regulators early next year. Haas added that an "accelerated approval was possible" as well.